![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Gives OK for Merck’s Keytruda for Melanoma
NICE Gives OK for Merck’s Keytruda for Melanoma
November 26, 2018
NICE has recommended NHS coverage for Merck’s Keytruda (pembrolizumab) for the treatment of certain melanoma patients.
The institute’s recommendation is for adults who have melanoma that has progressed to the lymph nodes. The recommendation applies to patients that have already undergone surgery to remove their melanoma.
The drug will become available through the NHS after it receives a marketing authorization, anticipated in early December.
Upcoming Events
-
21Oct